This understanding positions Rac1 as a promising therapeutic target, particularly in patients with obesity-related metabolic comorbidities, providing a rationale for further exploration of Rac1 inhibition in mitigating metastatic burden​. This evidence concerns the gene RAC1 and Obesity.